POINT: Should LAMA/LABA Combination Therapy Be Used as Initial Maintenance Treatment for COPD? Yes

Chest: The Journal of Circulation, Respiration and Related Systems

Mario Cazzola^1¹  Maria Gabriella Matera^2² 

[1] Department of Experimental Medicine and Surgery, University of Rome “Tor Vergata”, Rome, Italy^1;Unit of Pharmacology, Department of Experimental Medicine, University of Campania “Luigi Vanvitelli”, Naples, Italy^2

关键词: AE;    adverse event;    ASM;    airway smooth muscle;    CV;    cardiovascular;    FDC;    fixed-dose combination;    GOLD;    Global Initiative for Chronic Obstructive Lung Disease;    LABA;    long-acting β2-agonist;    LABD;    long-acting bronchodilator;    LAMA;    long-acting muscarinic antagonist;    MCID;    minimum clinically important difference;    SAE;    severe adverse event;    SGRQ;    St. George’s Respiratory Questionnaire;    TDI;    transitional dyspnea index;   

DOI  :  10.1016/j.chest.2018.06.022

学科分类：呼吸医学

来源: American College of Chest Physicians

【 摘 要 】

A general question to be addressed to optimize use of bronchodilators in COPD is “When can we add a second bronchodilator with a different mechanism of action?”¹ According to the latest version of the Global Initiative for Chronic Obstructive Lung Disease (GOLD) strategy, initial therapy should be a long-acting bronchodilator; the use of dual bronchodilation with a long-acting muscarinic antagonist (LAMA) plus a long-acting β₂-agonist (LABA) should be considered if symptoms are not improved with single agents.

【 授权许可】

CC BY